Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer

Prostate

Volumn 63, Issue 3, 2005, Pages 240-251

  Antognelli, Cinzia ^a   Mearini, Luigi ^a   Talesa, Vincenzo Nicola ^a   Giannantoni, Antonella ^a   Mearini, Ettore ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

CYP17; GSTP1; Metabolizing genes; Polymorphisms; PON1; Prostate cancer

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CARCINOGEN; CYTOCHROME P450 17; GENE PRODUCT; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE P1; ISOLEUCINE; UNCLASSIFIED DRUG; VALINE; XENOBIOTIC AGENT;

ADULT; AGED; ALLELISM; ARTICLE; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; CYP17 GENE; GENE; GENETIC POLYMORPHISM; GENETIC TRAIT; GENOTYPE; GLEASON SCORE; GSTP1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PON1 GENE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; ALLELES; ARYLDIALKYLPHOSPHATASE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HOMOZYGOTE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE;

EID: 17644406044     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20184     Document Type: Article

References (46)

1. Greenlee RT, Murray T, Bold en S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Finnish Cancer Registry. Cancer Incidence in Finland 1998. Cancer statistics of The National Research and Development Centre for Welfare and Health. Cancer Society of Finland publication available at www.cancerregistry. fi/v2000/v2000002oi. htlm (year 2000).
3. Sakr WA, Grignon DJ, Crissman JD, Heil Brun LK, Cassin BJ, Pontes JJ, Haas GP. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: An autopsy study of 249 cases. In Vivo 1994;8:439-443.
4. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000; 85:60-67.
5. Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagmer RP, Howe GR, Buech JD, Hankin J, Dreon DM, West DW. Prostate cancer in relation to diet, physical activity, and body size in Blacks, Whites, and Asians in the United States and Canada. J Natl Cancer Inst 1995;87:652-661.
6. Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968;40:43-68.
7. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991;63:963-966.
8. Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC, Willett WC. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 1993;85:1571-1579.
9. Gann PH, Hennekens CH, Sacks FM, Grodstein F, Giovannucci EL, Stampfer MJ. Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst 1994;86:281-286.
10. Page WF, Braun MM, Partin AW, Caporaso N, Walsh P. Heredity and prostate cancer: A study of World War II veteran twins. Prostate 1997;33:240-245.
11. Ahlbom A, Lichtenstein P, Malmstrom H, Feychting M, Hemminki K, Pedersen NL. Cancer in twins: Genetic and nongenetic familial risk factors. J Natl Cancer Inst 1997;89:287-293.
12. Gronberg H, Damber L, Damber JE. Studies of genetic factors in prostate cancer in a twin population. J Urol 1994;152:1484-1489.
13. Latil AG, Azzouzi R, Cancel GS, Guillame EC, Cochan-Priollet B, Berthon PL, Cussenot O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001;92:1130-1137.
14. Chen C. Risk of prostate cancer in relation to polymorphisms of metabolic genes. Epidemiol Rev 2001;23:30-35.
15. Marchesani M, Hakkarainen A, Tuomainen TP, Kaikkonen J, Pukkala E, Uimari P, Seppala E, Matikainen M, Kallioniemi OP, Schleutker J, Lehtihaki T, Salonen JT. New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finish men. J Natl Cancer Inst 2003;95(11):812-818.
16. Stanford JL, Noonan EA, Iwasaki L, Kolb S, Chadwick RB, Feng T, Ostrander EA. A polymorphism in the CYP17 gene and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002;11: 243-247.
17. Gsur A, Bernhofer G, Hinteregger S, Haidinger G, Schatel G, Madersbacher S, Marberger M, Vutuc C, Micksche M. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer 2000;87:434-437.
18. Wadelius M, Andersson AO, Johansson JE, Wadelius C, Rane E. Prostate cancer associated with CYP17 genotype. Pharmacogenetics 1999;9:635-639.
19. Nelson WG, De Marzo AM, DeWeese T. The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention. Urology 2001;57(Suppl 4A):39-45.
20. Yamada Y, Watanabe M, Murata M, Yamanaka M, Kubota Y, Ito H, Katoh T, Kawamura J, Yatani R, Shiraishi T. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5α-reductase type II (SRD5A2) genes on prostate cancer risk among the Japanese population. Int J Cancer 2001;92:683-686.
21. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998;31:329-336.
22. Ames BN. Dietary carcinogens and anticarcinogens. Oxygen radicals and degenerative diseases. Science 1983;221:1256-1264.
23. Goldstein BD, Witz G. Free radicals and carcinogenesis. Free Radic Res Commun 1990;11:3-10.
24. Gardemann A, Philipp M, HeB K, Katz N, Tillmanns H, Haberbosch W. The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease. Atherosclerosis 2000;152:421-431.
25. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphisms is reserved with diazoxon, soman, and sarin. Nat Genet 1996;14:334-336.
26. Ferrè N, Camps J, Fernandez-Ballart J, Arija V, Murphy MH, Cerveco S, Biarnes E, Vilella E, Tous M, Joven J. Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin Chem 2003;49(9):1491-1497.
27. Weber WW. Influence of heredity on human sensitivity to environmental chemicals. Environ Mol Mutagen 1995;25(Suppl 26): 102-114.
28. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:73-76.
29. Fan YS, Sasi R, Lee C, Winter JSD, Waterman MR, Lin CC. Localization of the human CYP17 gene (cytochrome P-45017α) to 10q24.3 by fluorescence in situ hybridization and simultaneous chromosome banding. Genomics 1992;14:1110-1111.
30. Picardo-Leonard J, Miller WL. Cloning and sequence of the human gene for p450c17 (steroid 17α-hydroxylase/17,20lyase): Similarity with the gene for P450c21. DNA 1987;6:439-448.
31. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urology 1984;132:474.
32. The Japanese Urological Association and the Japanese Society of Pathology. General Rules for Clinical and Pathological Studies on Prostate Cancer. 2nd edition. Tokyo, Japan: Kanahara-Shuppan Co.; 1992.
33. Gleason DF, the VACURG. Histological grading and clinical staging of prostatic carcinoma. In: Tannenbaum Myron, editor. Urologic pathology, Philadelphia: Lea & Febiger; 1997. pp 171-179.
34. International Union Against Cancer. Urological tumours: Prostate. In: Hermanek P, Sobin H, editors. TNM classification of malignant tumours. 4th edition. Berlin: Springer-Verlag; 1992. pp 141-144.
35. Nebert DW, McKinnon RA, Puga A. Human drug-metabolizing enzyme polymorphisms: Effects on risk of toxicity and cancer. [Review] [96 refs]. DNA Cell Biol 1996;15:273-280.
36. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: Regulation of GST and the contribution of the enzyme to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995;30:445-460.
37. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998;394:284-287.
38. Partin AW, Coffey DS. The molecular biology, endocrinology, and physiology of the prostate and seminal vesicles. In: Walsh PC, Retik ED, et al., editors. Canbell's urology. 7th edition. Philadelphia: Saunders WB Co.; 1998. pp 1381-1428.
39. Perera PT. Environmental and cancer: Who are susceptible? [Review] [50 refs]. Science 1997;278:1068-1073.
40. Habuchi T, Liqing Z, Suzuki T, Sasaki R, Tsuchiya N, Tachiki H, Shimoda N, Satom S, Sato K, Kakehi Y, Kamoto T, Ogawa O, Kato T. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 2000;60:5710-5713.
41. Makridakis N, Reichardt J, Pike M, et al. Genetic control of human androgen metabolism by the CYP17 and SRD5A2 genes. Am J Hum Genet 1997;61(Suppl):A257.
42. Li DH, Randerath K. Association between diet and age-related DNA modifications (I-compounds) in rat liver and kidney. Cancer Res 1990;50:3991-3996.
43. Li D, Randerath K. Modulation of DNA modification (I-compound) levels in rat liver and kidney by dietary carbohydrate, protein, fat, vitamin, and mineral content. Mutat Res 1992;275:47-56.
44. Harries LW, Stubbins MJ, Forman D, Howard GCW, Wolf CR. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997;18(4):641-644.
45. Lee WH, Morton RA, Epstein JL, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG. Cytidine methylation of regulatory sequences near the Pi class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994;91:11733-11737.
46. Zimniak P, Nanduri B, Pikula S, Bandorowicz-Pikula J, Singhal SS, Srivastava SK, Awasthi S, Awasthi YC. Naturally occuring human glutathione S-transferase GSTP1.1 isoforms with isoleucine and valine at position 104 differ in enzymatic properties. Eur J Biochem 1994;244:893-899.